Buy Letrozole (Femara) online

Price: 581 UAH

Known as original brand(s)

Femara

Buy Letrozole (Femara) online with delivery. Browse medicines that contain Letrozole, compare doses and prices.

Letrozole is a highly selective third-generation non-steroidal aromatase inhibitor originally marketed under the brand name Femara. It is widely used in gynecologic oncology for the endocrine management of hormone receptor-positive breast cancer in postmenopausal women, as well as in reproductive medicine for ovulation induction.

The mechanism of action of letrozole involves competitive binding to the heme group of the aromatase enzyme (cytochrome P45019), which catalyzes the conversion of androgen precursors into estrogens. This results in profound suppression of circulating estrogen levels (by 97–99%), effectively eliminating the hormonal stimulus for estrogen-dependent tumors.

Clinical utilization of letrozole reduces recurrence and metastatic risks in early and advanced breast cancer settings, while endocrinological applications facilitate follicular development and ovulation in anovulatory infertility (such as polycystic ovary syndrome, PCOS).

Wikipedia page
Letrozole (Femara)

Indications

Letrozole is indicated in clinical practice for the following conditions:

  • Breast Cancer (Adjuvant Therapy): Treatment of postmenopausal women with estrogen receptor-positive early invasive breast cancer following 5 years of initial adjuvant tamoxifen therapy.
  • Advanced Breast Cancer: First-line treatment of postmenopausal women with advanced hormone-dependent breast cancer, or disease progression following prior antiestrogen therapy.
  • Ovulation Induction (Off-label): Treatment of anovulatory infertility (e.g., in PCOS) to stimulate follicular growth.

Dosage and administration

Letrozole is intended for oral administration:

  • For Breast Cancer: The recommended standard dose is 2.5 mg (one tablet) taken once daily, with or without food. Adjuvant treatment may continue for up to 5 years or until tumor relapse.
  • For Ovulation Induction: Typically dosed at 2.5 mg to 5 mg daily, initiated on cycle days 3 through 7 under the supervision of a fertility specialist.
  • Monitoring: Patients with uncertain menopausal status must undergo baseline hormonal evaluation (LH, FSH, and estradiol) to confirm postmenopausal status prior to oncological use.

Letrozole is contraindicated in the following cases:

  • Premenopausal Status: Active ovarian function / premenopausal women (except for supervised fertility induction protocols).
  • Pregnancy and Lactation: Pregnancy and breastfeeding periods due to severe teratogenic risks.
  • Hypersensitivity: Known hypersensitivity to letrozole or any core excipients.
  • Severe Hepatic Impairment: Severe hepatic dysfunction (Child-Pugh Class C).

Treatment with letrozole may cause the following adverse reactions:

  • Vascular & General: Hot flashes, hyperhidrosis, fatigue, asthenia, and peripheral edema.
  • Musculoskeletal: Arthralgia, myalgia, bone pain, and decreased bone mineral density leading to osteoporosis and fracture risk.
  • Nervous System: Headache, dizziness, insomnia, anxiety, and depression.
  • Gastrointestinal: Nausea, vomiting, dyspepsia, altered bowel habits, and transient liver enzyme elevations.
  • Dermatologic: Rash, dry skin, and alopecia.
  • Cardiovascular: Hypertension and rare ischemic events.

Frequently Asked Questions

Letrozole is an oral antineoplastic medication classified as a potent, non-steroidal aromatase inhibitor. It acts by competitively and reversibly binding to the heme of the cytochrome P450 aromatase enzyme, which catalyzes the conversion of androgens (such as testosterone and androstenedione) into estrogens (estradiol and estrone) in peripheral tissues. In postmenopausal women—where ovarian estrogen synthesis has ceased—adipose tissue and muscle become the primary sources of estrogen production. Letrozole suppresses aromatase activity by 97% to 99%, drastically reducing circulating estrogen levels and starving hormone-dependent breast tumors of the signals required for proliferation.
Letrozole is indicated for the management of hormone receptor-positive (HR+) early or advanced breast cancer in postmenopausal women. It is utilized across multiple therapeutic settings: as upfront adjuvant treatment following surgery, as sequential adjuvant therapy following a standard course of tamoxifen, as extended adjuvant therapy, and as first-line or subsequent endocrine therapy for advanced or metastatic disease. Additionally, letrozole is occasionally utilized off-label in reproductive endocrinology to induce ovulation.
The standard recommended dose of letrozole is 2.5 mg (one tablet) taken orally once daily. The tablet should be swallowed whole with water at approximately the same time each day. A key pharmacokinetic advantage of letrozole is that its administration is independent of food intake—it can be taken with or without meals, as food does not clinically alter its systemic absorption. For early-stage breast cancer, the standard duration of adjuvant therapy is typically 5 years.
Profound estrogen suppression caused by letrozole accelerates bone turnover and mineral resorption, increasing the risk of bone loss, osteopenia, osteoporosis, and fragility fractures. Baseline bone mineral density screening via DEXA scan is mandatory before starting treatment. To counteract skeletal degradation, patients are routinely prescribed daily calcium and vitamin D supplementation. If bone mineral density declines significantly, clinicians introduce targeted antiresorptive medications such as bisphosphonates or denosumab.
The adverse event profile of letrozole is primarily attributable to systemic estrogen deprivation. The most frequently reported side effects include vasomotor symptoms (hot flashes, night sweats), fatigue, headache, vaginal dryness, insomnia, and musculoskeletal complaints such as arthralgia and myalgia. Joint stiffness and pain affect a significant proportion of patients and can impact daily functioning. Management approaches for persistent arthralgia include regular low-impact aerobic exercise, weight management, and short-term analgesic support under medical guidance.

Medicines containing Letrozole

-13%
Letronat
View
Natco

Letronat

Letrozole
2.5 mg 30 tablets
581₴ 671₴
✅ All products loaded (1)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00